OncoSec Medical(DE:ONMA)
€0.14+0.00 (+64.71%)
DE:ONMA
OncoSec Medical financials statements
€0.14
At close:+0.00 (+64.71%)
OncoSec Medical (ONMA) Ratios
1 Followers
OncoSec Medical Ratios
DE:ONMA's free cash flow for Q2 2023 was $-6.63M. For the 2023 fiscal year, DE:ONMA's free cash flow was decreased by $-15.96K and operating cash flow was $-6.61M. See a summary of the company’s cash flow.
| Ratios | Jul 22 | Jul 21 | Jul 20 | Jul 19 | Jul 18 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.30 | 6.18 | 2.36 | 5.73 | 4.89 |
| Quick Ratio | 2.30 | 6.18 | 2.36 | 5.73 | 4.89 |
| Cash Ratio | 1.85 | 5.77 | 2.10 | 5.05 | 0.65 |
| Solvency Ratio | -2.10 | -2.42 | -2.57 | -5.35 | -5.30 |
| Operating Cash Flow Ratio | -4.84 | -5.25 | -3.42 | -5.83 | -3.97 |
| Short-Term Operating Cash Flow Coverage | -34.32 | -33.87 | -34.19 | -346.27 | 0.00 |
| Net Current Asset Value | $ -527.49K | $ 30.98M | $ 6.79M | $ 22.89M | $ 21.30M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.28 | 0.13 | 0.26 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 1.01 | 0.19 | 0.56 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.50 | 0.16 | 0.36 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.03 | 0.00 | 0.00 |
| Financial Leverage Ratio | 3.58 | 1.48 | 2.16 | 1.23 | 1.32 |
| Debt Service Coverage Ratio | -34.56 | -35.26 | -42.44 | -342.93 | 0.00 |
| Interest Coverage Ratio | -1768.80 | -3051.02 | -8488.28 | -7993.87 | 0.00 |
| Debt to Market Cap | 0.32 | 0.17 | 0.21 | 0.05 | 0.00 |
| Interest Debt Per Share | 3.47 | 4.90 | 10.42 | 0.27 | 0.00 |
| Net Debt to EBITDA | 0.17 | 0.83 | 0.30 | 0.83 | 0.12 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 91.11% | 94.93% | 97.98% | 100.00% | 100.00% |
| EBT Per EBIT | 101.36% | 98.35% | 99.35% | 99.53% | 108.39% |
| Return on Assets (ROA) | -156.23% | -80.26% | -141.30% | -101.28% | -129.39% |
| Return on Equity (ROE) | -558.64% | -118.63% | -304.63% | -124.70% | -170.72% |
| Return on Capital Employed (ROCE) | -242.78% | -100.14% | -214.63% | -122.08% | -147.99% |
| Return on Invested Capital (ROIC) | -195.00% | -91.14% | -196.04% | -121.67% | -147.99% |
| Return on Tangible Assets | -158.98% | -80.91% | -141.30% | -101.28% | -129.39% |
| Earnings Yield | -1166.56% | -629.17% | -608.44% | -1923.31% | -786.62% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.10 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | -3564.78 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 3564.78 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -17.99 | -27.94 | -44.10 | -90.47 | -127.33 |
| Free Cash Flow Per Share | -18.13 | -28.48 | -44.10 | -90.50 | -127.69 |
| Dividend Paid and CapEx Coverage Ratio | -131.25 | -52.27 | 0.00 | -2775.77 | -356.41 |
| Capital Expenditure Coverage Ratio | -131.25 | -52.27 | 0.00 | -2935.03 | -356.41 |
| Operating Cash Flow Coverage Ratio | -5.20 | -5.71 | -4.24 | -346.27 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -1105.25% | -593.32% | -477.29% | -1843.13% | -468.06% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.09 | -0.16 | -0.16 | -0.05 | -0.13 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 0.48 | 0.19 | 0.50 | 0.06 | 0.22 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.09 | -0.17 | -0.21 | -0.05 | -0.21 |
| Price-to-Operating Cash Flow Ratio | -0.09 | -0.17 | -0.21 | -0.05 | -0.21 |
| Price-to-Earnings Growth (PEG) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 |
| Enterprise Value Multiple | 0.09 | 0.68 | 0.13 | 0.78 | -0.04 |
| Enterprise Value | -3.20M | -31.45M | -5.59M | -23.49M | 1.17M |
| EV to EBITDA | 0.09 | 0.68 | 0.13 | 0.78 | -0.04 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | 0.10 | 0.74 | 0.17 | 0.81 | -0.05 |
| EV to Operating Cash Flow | 0.10 | 0.75 | 0.17 | 0.81 | -0.05 |
| Tangible Book Value Per Share | 3.21 | 25.16 | 18.46 | 75.73 | 125.70 |
| Shareholders’ Equity Per Share | 3.42 | 25.46 | 18.46 | 75.73 | 125.70 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.09 | 0.05 | 0.02 | -0.00 | -0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -19.13 | -30.20 | -56.22 | -94.43 | -214.59 |
| Tax Burden | 0.91 | 0.95 | 0.98 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.94 | 0.93 | 0.78 | 0.96 | 0.59 |
Currency in USD
